Every year, in March, the IQVIA Institute distributes a detailed report on global R&D trends and activities. Our readers may find this to be an interesting source of information. Today’s focus is on R&D investment trends and highlights these key facts:

• Biopharma investment flows and deal activity in life sciences companies in the U.S. were restored to pre-pandemic levels after two years of heightened activity during the pandemic.

• Venture capital investments into U.S. companies declined 39% in 2022 but remain 25% above 2019 levels, while investments into European companies declined 74% in 2022 and are 47% below 2019 levels.

• U.S. venture capital deal activity and investment flows remain high at $42.1Bn, down from $54.8Bn in 2021 but above the $27.3Bn in 2019.

• Over the past five years, deal activity has shifted geographically to include more companies headquartered in China and South Korea and fewer Europe-based companies. While North American companies continue to represent the largest number of deals, they declined slightly over the five-year period.

• Deal activity in 2022 returned to pre-pandemic levels, with a 25% contraction of R&D collaboration versus 2019.

• The 15 largest pharmaceutical companies invested a record $138Bn in 2022 in R&D expenditure, an increase of 43% since 2017 and representing 18.8% of their recorded sales.

• The number of deals between pharma companies dropped by 25% from 2021 to 2022, with an increase in the percentage of deals involving emerging biopharma with larger companies.1

Read more here.

References

  1. Global Trends in R&D 2023. (n.d.). IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred